Emerging Therapies: Nucala (US) is a three-wave, syndicated, detailed, expanded analysis that tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic asthma. The series is based on primary research data collected at one month, six months, and one year after Nucala became commercially available. Along with awareness and sources of familiarity, the reports assess U.S. pulmonologists’ and allergists’ trial, adoption, and use of Nucala, including anticipated future trends. The analysis also provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, GlaxoSmithKline’s promotional efforts, and benchmarking against previously launched immune biologics. This module also includes an overview and pipeline analysis of asthma therapies in early- to late-phase clinical development, as well as detailed profiles of, expert insight on, and commercial outlook for select therapies in late-phase development.